Washington, D.C. 20002, or call (202) 512–7350.

Authority: Federal Advisory Committee Act. Pub. L. No. 92–463, Section 10(a)(2), 86 Stat. 770, 774 (1972) (current version at 5 U.S.C. app. section 10(a)(2) (1988); 41 CFR 101–6.1015 (1990).

Dated: September 10, 1996.

Ronald S. Young,

Executive Director.

[FR Doc. 96–24070 Filed 9–18–96; 8:45 am]

BILLING CODE 1610–01–M

GENERAL SERVICES ADMINISTRATION

Public Buildings Service; Notice of Availability of Final Supplemental Environmental Impact Statement; Proposed Pacific Highway Port of Entry Expansion, Blaine, Whatcom County, WA

Pursuant to section 102(2)(C) of the National Environmental Policy Act (NEPA) of 1969, as amended, as implemented by the Council on Environmental Quality (40 CFR Parts 1500–1508), the General Services Administration (GSA) has filed with the Environmental Protection Agency, and made available to other government and interested private parties, the Final Supplemental Environmental Impact Statement (FSEIS) for the proposed expansion at the Pacific Highway Port of Entry in Blaine, Washington.

The FSEIS is on file and a copy may be obtained from U.S. General Services Administration, Region 10, Attention: Donna M. Meyer, 400 15th Street, SW., Auburn, Washington 98001, (206) 931–7675. A limited number of copies of the FSEIS are available to fill single copy requests. Loan copies are available for public review at the Blaine City Library, 610 Third Street, Blaine, Washington.

Written commends regarding the Final Supplemental Environmental Impacted Statement may be submitted until October 14, 1996 and should be addressed to General Services Administration in care of GSA's EIS subconsultant, Berger/ABAM Engineers, Inc., 33301 Ninth Avenue South, Federal Way, Washington, 98003–6395.

Dated: September 6, 1996.

L. Jay Pearson,

Regional Administrator (10A).

[FR Doc. 96–24020 Filed 9–18–96; 8:45 am]

BILLING CODE 6820–23–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Ceftiofur Sodium for Sheep; Availability of Data

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of target animal safety and effectiveness, and human food safety data to be used in support of a new animal drug application (NADA) or supplemental NADA for the use of ceftiofur sodium sterile powder, reconstituted with sterile water, as an injectable for treating certain respiratory diseases of sheep. The data, contained in Public Master File (PMF) 5544, were compiled under National Research Support Project-7 (NRSP–7), a national agricultural research program for obtaining clearances for use of new drugs in minor animal species and for special uses.

ADDRESSES: Submit NADA's or supplemental NADA's to the Document Control Section (HFV–199), Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855.

FOR FURTHER INFORMATION CONTACT: Naba K. Das, Center for Veterinary Medicine (HFV–133), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1659.

SUPPLEMENTARY INFORMATION: The use of ceftiofur sodium sterile powder, reconstituted as a sterile aqueous injection, to treat sheep for respiratory disease is a new animal drug use under section 201(v) of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 321(v)). As a new animal drug, ceftiofur is subject to section 512 of the act (21 U.S.C. 360b), which requires that its uses in sheep be the subject of an approved NADA or supplemental NADA. Sheep are a minor species under § 514.1(d)(1)(ii) (21 CFR 514.1(d)(1)(ii)).

The NRSP–7 Project, Western Region, University of California, Davis, CA 95616, has provided data and information that demonstrate safety and effectiveness to the target animal and human food safety for ceftiofur sterile powder, reconstituted as a sterile aqueous injectable solution for intramuscular use in sheep, to treat sheep respiratory disease (pneumonia) associated with *Pasteurella haemolytica* and/or *P. multocida*. NRSP–7 did not provide information concerning potential environmental impacts of the manufacturing process. Such information is required upon submission of an application relying on this file to support approval.

The data and information on safety and effectiveness are contained in PMF 5544. Sponsors of NADA's or supplemental NADA's may, without further authorization, reference the PMF to support approval of an application filed under § 514.1(d). An NADA or supplemental NADA must include, in addition to a reference to the PMF, animal drug labeling and other information needed for approval, such as data supporting extrapolation from a major species in which the drug is currently approved, or authorized reference to such data, and data concerning manufacturing methods, facilities and controls, and information addressing potential environmental impacts of the manufacturing process.

In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information in this PMF submitted to support approval of an application may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Dated: September 4, 1996.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 96–24074 Filed 9–18–96; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 96N–0074]

Sperti Drug Products, Inc., et al.; Withdrawal of Approval of 40 New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing 40 new drug applications (NDA's). The basis for the withdrawals is that the holders of the applications have repeatedly failed to file required annual reports on these NDA's.

EFFECTIVE DATE: September 19, 1996.

FOR FURTHER INFORMATION CONTACT: Olivia A. Vieira, Center for Drug Evaluation and Research (HFD–7), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–594–1046.

SUPPLEMENTARY INFORMATION: The holders of approved applications to